GLP-1 Pills vs Injections in 2026: Which Works Better for You?

Four GLP-1 products are FDA-approved for chronic weight management: two weekly injections (Wegovy and Zepbound) and two daily pills (the Wegovy pill and Foundayo). Many products sold online are none of these four, so it helps to know exactly what each name refers to before comparing.

Weekly injections: Wegovy and Zepbound

• Wegovy (semaglutide) received FDA approval for chronic weight management on June 4, 2021. It acts on the GLP-1 receptor.
• Zepbound (tirzepatide) was approved on November 8, 2023. It acts on two receptors, GLP-1 and GIP, which is the usual explanation for its bigger trial result.

Both are injected under the skin once a week from a pre-filled pen, starting low and increasing over several months. Telehealth providers also sell the same two molecules as compounded injections made by state-licensed pharmacies, for a fraction of the brand price and without FDA approval of the product. Most providers on this site use that route, and most "injection" prices you see online refer to it.

Daily pills: the Wegovy pill and Foundayo

• The Wegovy pill is a 25 mg once-daily semaglutide tablet, approved in December 2025 as the first oral GLP-1 for chronic weight management.
• Foundayo is orforglipron, a small-molecule GLP-1 receptor agonist from Eli Lilly, approved on April 1, 2026.

Both pills are brand-name, prescription-only and FDA-approved, and neither is compounded. A third tablet, Rybelsus, is lower-dose oral semaglutide approved for type 2 diabetes rather than weight management, and it produces less weight loss at diabetes doses.

What about compounded GLP-1 tablets and drops?

Some telehealth programs sell compounded oral semaglutide or tirzepatide as tablets, under-the-tongue drops or troches. These are not the Wegovy pill. They have no trial data of their own, and a peptide swallowed without the formulation work the approved tablet received is poorly absorbed. They appear here only as a caution: a compounded "pill" is an unstudied product, not a discount Wegovy pill. The rest of this guide compares the four approved products and the compounded injections, since those have evidence and published prices behind them.

In their main trials, Zepbound averaged 20.9% weight loss, Wegovy injections 14.9%, the Wegovy pill 13.6% and Foundayo 11.2%. Each figure comes from a separate randomized, placebo-controlled, manufacturer-run trial that added lifestyle advice, with different lengths and populations. No trial has tested a pill against an injection directly, so each result should be read against its own placebo group rather than as a head-to-head contest.

Why you see two different numbers for each drug

Every trial reports two valid figures. The table uses the treatment-policy (or treatment-regimen) result, which counts everyone randomized whether or not they stayed on the drug. Manufacturers also publish an on-treatment result for people who took the drug as directed until the end: 22.5% for tirzepatide 15 mg, 16.6% for the Wegovy pill and 12.4% for Foundayo. Marketing usually quotes the on-treatment figure. We use the treatment-policy figure because it better reflects what happens across a real group of patients. The two answer different questions and do not contradict each other.

What the results mean for pills vs injections

• Injectable tirzepatide is still the strongest GLP-1 on average, pill or pen, about six percentage points ahead of semaglutide at the top dose, and a substantially larger share of SURMOUNT-1 participants lost 20% or more.
• The Wegovy pill and the Wegovy injection are close: 13.6% vs 14.9% in their own trials, and the OASIS 4 authors describe the pill's effect as similar to the weekly injection.
• Foundayo has the lowest published figure of the four, yet it still beat every non-GLP-1 pill ever approved. In ATTAIN-1, 19% of people on the top dose lost 20% or more of their body weight, compared with 3% on placebo.

What the averages do not tell you

These are averages at the full maintenance dose after a long dose escalation, so they describe roughly month fifteen, not month two. In STEP 1, about a third of participants lost 20% or more while some lost very little, and nothing on an intake form predicts which group you will land in. Every trial also included lifestyle counseling that most telehealth programs do not offer. Read the trial results as the upper range a well-managed, fully dosed course can approach, not as a promise for either format.

Because swallowed semaglutide is mostly broken down in the gut, the Wegovy pill needs 25 mg a day to match what a 2.4 mg weekly injection achieves. Semaglutide is a peptide, and only a small fraction of a swallowed peptide reaches the bloodstream. The tablet therefore carries far more drug and must be taken under conditions that protect the little that gets absorbed, which is where the empty-stomach rule in the next section comes from. It is also why compounded "oral semaglutide" made without that formulation work is a different, unstudied product.

Foundayo solves the problem differently. Orforglipron is a small molecule built to be absorbed through the gut like most everyday tablets, so it can be taken at any time, with or without food. On the published numbers, its trade-off is less average weight loss than semaglutide in either form. Injections avoid the absorption problem altogether: the drug goes under the skin and straight into circulation, which is why a weekly dose of a few milligrams is enough.

The Wegovy pill is taken daily on an empty stomach with a 30-minute wait, Foundayo is taken daily at any time, and the pens are used once a week. For most people this is the difference they feel day to day, and it shows that "pills are easier" is not always true.

• The Wegovy pill has the strictest routine. Waiting 30 minutes every morning before coffee, breakfast or other medicines is easy for some people and a deal-breaker for others. Absorption falls if you skip the wait, so the rule is not optional.
• Foundayo has the easiest routine. No timing, no food rule and no needle, which is its main appeal for people who take morning medicines or dislike timed routines.
• The weekly pen is easy in a different way. It means 52 small, sealed, pre-measured doses a year with nothing to remember in between. The needle is short and thin, and most people who were nervous about it say the first injection settled their worries.
• The compounded vial is the least convenient and the most prone to mistakes, because you measure the dose yourself. The FDA's statement on unapproved GLP-1 drugs records adverse-event reports caused by vial dosing errors, and our guide to reading a compounded prescription explains how units work.

Compounded injections cost $49-$299 a month, brand pills $149-$349 self-pay, and brand pens paid in cash cost the most; coverage can bring a pill to $25 or $50. Where you buy matters far more than whether it is a pill or a pen. Two facts drive the whole table: brand products, pill or pen, carry brand prices for cash buyers, and compounded injections cost a fraction of that because the product is not FDA-approved. Every figure below is either a provider's own published price that we verified (compounded and Ro prices, checked on each provider's site on October 16, 2026 for the price index and in August 2026 for Ro's brand products) or a manufacturer price as reported by the dated source linked, which we have not verified.

What does a full first year cost?

First-month prices can mislead in either direction, so add up twelve months. At Ro's cash prices, a year on the Wegovy pill totals roughly $4,300-$5,100: $3,438 for the medicine plus $853-$1,678 in membership, depending on tier. A year of compounded semaglutide ranges from $588 on welludr's 12-month plan to $828-$2,348 at month-to-month providers, and compounded tirzepatide adds about $480-$1,320. A year of brand Zepbound paid in cash reaches five figures. Only the $25 commercial savings cards and Medicare's $50 pilot come in below compounded prices, so check your coverage before you think about format. Our month 1 vs year one guide runs these totals for every provider we track, and Wegovy pill price online covers every route to the semaglutide pill.

No. GLP-1 pills and injections share the same side-effect profile: mostly digestive, mostly in the first weeks and mostly around dose increases. All four products act on the same receptor family. In OASIS 4, 74% of people taking the Wegovy pill had a gastrointestinal adverse event compared with 42% on placebo, led by nausea and diarrhea. In ATTAIN-1, gastrointestinal events were also the most common with Foundayo and were usually mild to moderate. The injection labels, summarized on MedlinePlus for semaglutide and tirzepatide, list the same top effects: nausea, diarrhea, vomiting, constipation, stomach pain and reduced appetite.

The serious warnings are the same as well:

• Every product here carries the class boxed warning about thyroid C-cell tumors seen in rodents, and none should be used by people with a personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2.
• The labels also warn about pancreatitis and gallbladder disease.
• Tirzepatide's label adds that it can make oral contraceptives less effective for four weeks after starting and after each dose increase.

Neither pill trial found a safety signal beyond the known class profile. What really changes how well you tolerate a GLP-1 is the titration: how low you start and how slowly you increase. A clinician who manages that carefully, and slows the schedule if side effects linger, matters more than whether you take a tablet or use a pen. Our semaglutide side-effects guide explains what helps during the first weeks on either format.

Brand pills and pens can be covered by commercial insurance or Medicare's GLP-1 Bridge; compounded injections never qualify. This is where format does change the answer, because the brand pills launched inside programs compounded products cannot join.

Commercial insurance. If your plan covers the drug for weight management, each manufacturer has a savings card. Lilly's brings Foundayo to $25 a month, and Novo Nordisk's is reported to bring the Wegovy pill as low as $25, limited to $100 of savings per 30-day supply. Neither card works with Medicare, Medicaid or other government plans. Coverage itself is the hurdle: many plans still exclude weight-management GLP-1s or require prior authorization, and our insurance guide shows how to check your formulary. If your plan covers a brand injection instead, the same applies to Wegovy and Zepbound pens, and a telehealth prescriber such as Ro can handle the prior authorization and bill the medicine as a separate line item.

Medicare. From July 1, 2026 through December 31, 2027, the Medicare GLP-1 Bridge pilot gives eligible beneficiaries a flat $50 monthly copay for the Wegovy pill and injection, the Zepbound KwikPen and Foundayo. The $50 is the same at every dose and for both formats, so Medicare patients can choose on routine and results alone. Medicare does not cover compounded GLP-1s. See GLP-1s after 65 for what to ask your Part D plan.

Paying cash. Without coverage, compounded injections are the cheapest route by thousands of dollars a year, the brand pills are the cheapest FDA-approved route, and the brand pens cost the most of anything on this page.

No. Compounded GLP-1 injections are legal under specific conditions, but the products are not FDA-approved. Since most "injection" prices in this guide are compounded prices, it is worth being exact. Compounding means a licensed pharmacist prepares a medicine for an individual patient under a prescription. The FDA's human drug compounding page describes two federal frameworks:

• Section 503A: state-licensed pharmacies compounding for a specific patient. Nearly every telehealth GLP-1 program uses this route.
• Section 503B: registered outsourcing facilities producing larger batches under stricter oversight.

Compounded GLP-1s expanded while semaglutide and tirzepatide were on the FDA shortage list, which loosens compounding limits. That period has ended: the FDA declared the tirzepatide shortage resolved on December 19, 2024 and the semaglutide shortage on February 21, 2025. What remains legal is a patient-specific prescription in which the prescriber documents a clinical need the approved product does not meet.

Read the FDA's summary of its concerns before you buy. Compounded products are not reviewed for safety, effectiveness or quality before sale; the agency has received adverse-event reports that include vial dosing errors; some products contained salt forms of semaglutide that are not the approved active ingredient; and products sold without a prescription may be counterfeit.

None of this makes compounded injections a scam. It means quality depends on the pharmacy rather than a brand, and you are relying on the telehealth provider's choice of pharmacy. The providers on this site name their pharmacies, and that is the first thing we check. There is no compounded version of Foundayo, and no compounded oral product has evidence comparable to the Wegovy pill's, so if you want a pill, choose one of the two approved ones. Our compounded vs brand-name guide and the 503A vs 503B explainer go into more detail.

You can switch between formats with your prescriber's help, but stopping a GLP-1 usually means regaining much of the weight. Switching is more common than marketing suggests: from a pill to an injection after a plateau, from an injection to a pill when insurance changes, or from a brand pen to a compounded vial when a savings card ends. Every switch goes through the prescriber. There is no do-it-yourself conversion between a weekly 2.4 mg pen and a daily 25 mg tablet, or between semaglutide and orforglipron, and clinicians usually restart the dose escalation instead of jumping to an equivalent dose.

Whichever format you use, treat it as a long-term medicine, much like blood-pressure medication. In the STEP 1 extension, people who stopped semaglutide and the lifestyle program regained about two-thirds of the weight they had lost within a year (Wilding et al., Diabetes, Obesity and Metabolism, April 19, 2022). Plan your budget around that finding: pick the route whose second-year price you can keep paying, not the one with the cheapest first month. Our guide to what happens when you stop covers the tapering and maintenance approaches clinicians use.

Choose based on coverage first, then on whether you prioritize results, price or avoiding needles. Most readers fit one of these five situations:

1. Your insurance covers a GLP-1 for weight management. Use the covered product. At $25 a month, either pill or a covered pen beats every cash route here, and the price difference between the pills becomes negligible. Check your formulary first, because it outweighs every other factor on this page.

2. You have Medicare. Ask your Part D plan about the GLP-1 Bridge before comparing prices. With all four brand products at a flat $50, decide on routine and results: an injection for the bigger trial result, or Foundayo for the simplest routine.

3. You are paying cash and results matter most. The evidence favors tirzepatide, and a compounded injection is the only affordable way to get it: $89 a month on a 12-month plan or $119 with no commitment. See best tirzepatide online for every verified price, and remember it is not an FDA-approved product.

4. You are paying cash and will not inject. Ro offers the only verified telehealth route to an approved pill today, the Wegovy pill at $149 and then $299 plus membership. Foundayo's reference price is LillyDirect's reported $149-$349. The Wegovy pill has the larger trial result and Foundayo has no timing rules; Foundayo vs the Wegovy pill compares them in detail. Do not accept a compounded "pill" as a replacement.

5. You are paying cash and price decides. Compounded semaglutide injections from $49-$99 a month are the lowest prices in the market, and the weekly shot takes about thirty seconds that most people stop noticing by month two. What $100-$200 a month gets you shows what each price range buys.

In every case a licensed clinician decides based on your history rather than a table, and may decline to prescribe any of them.

Through a licensed telehealth provider: an online intake, a clinician review and, if appropriate, a prescription shipped to you or sent to your pharmacy. The process is the same for pills and injections, and it is the only legal way to get either:

1. Complete an online intake covering your weight, health history, medicines and goals.
2. A licensed clinician reviews it by questionnaire, message or video.
3. If appropriate, you get a prescription, filled by the provider's partner pharmacy and shipped to you, or sent to a pharmacy of your choice when insurance applies.
4. Follow-up continues as the dose increases.

For the brand pill, Ro is the provider we have verified. For compounded injections, every provider ranked in our weight-loss comparison completes that review before prescribing. The complete guide to GLP-1 weight loss online covers each step from intake to first dose, including how to check the pharmacy, refund terms if you are not approved, and what to ask before paying upfront.

This guide offers general information and is not medical advice. GLP-1 medicines require assessment and supervision by a licensed healthcare provider, who decides whether any of them suits you.